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Abstract
Background: At present, researchers’ attention has been concentrating on NDRG2 (N-Myc downstream-regulated
gene 2) as a new gene candidate in the development and progression of papillary thyroid carcinoma (PTC).
NDRG2, together with NDRG1, NDRG3 and NDRG4 are members of the NDRG family, a new class of genes, inhibited
by N-Myc oncogene.
Aim: The aim of our study was to evaluate NDRG2 mRNA expression in the primary PTC and its metastases to
regional lymph nodes.
Materials and methods: Postoperative tissue and macroscopically changed lymph nodes of sixteen (16) patients
with PTC constituted the studied material. In this group, metastases of the cancer to regional lymph nodes were
confirmed histopathologically in 8 cases. Quantitative evaluation of NDRG2 mRNA expression was performed by the
real-time polymerase chain reaction (real-time PCR) method.
Results: The mean values of NDRG2 mRNA expression in the primary tumour tissues were statistically significantly
lower vs. the levels of NDRG2 mRNA expression in macroscopically unchanged thyroid tissue (p < 0.0001). A
comparison of the mean NDRG2 mRNA expression of primary tumours and that of their metastases to regional
lymph nodes did not demonstrate any statistical differences (p > 0.05). A positive correlation was observed
between NDRG2 mRNA expression in primary tumour cells and in the cancer metastases to lymph nodes (Rs =
0.7857; p < 0.05). Factors, such as age, sex, tumour stage in TNM system, were of no significance for NDRG2 mRNA
expression level (p > 0.1).
Conclusion: The results of our study demonstrated decreased NDRG2 mRNA expression levels in PTC, when
compared to macroscopically unchanged thyroid tissue, which may point to the potential role of NDRG2 in the
development and progression of cancer in question.
Introduction
Molecular disorders, associated with papillary thyroid
carcinoma (PTC) development and progression, have for
many years been and still are the subject of extensive
and intensive research [1-4].
Currently, researchers’ attention has been concentrat-
ing on NDRG2 (N-Myc downstream-regulated gene 2), a
new candidate gene, taking part in the development and
progress of PTC. Deng et al. [5] were the first to have
identified the human NDRG2 (N-Myc downstream-regu-
lated gene 2). The to-date’s data indicate a significant
role of the NDRG family in the proliferation and differ-
entiation of cells. NDRG2 is localised on 14q11.2 chro-
mosome and encodes a protein of 41 kDa weight [6].
Studies of NDRG2 human gene expression at mRNA
level have demonstrated the presence of a transcript of
this gene in cells of the brain, the liver and the kidneys.
T h eh i g h e s te x p r e s s i o nl e v e l so ft h eg e n eh a v eb e e n
found in salivary glands, muscle and nervous cells, while
NDRG2 mRNA was almost undetectable in the thymus,
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Such patterns of expression suggest a reverse correlation
between the expression level of the gene and the cell
proliferation rate [7]. A reduced NDRG2 gene expres-
sion has also been observed in a number of human neo-
plasms, which suggests its role as a suppressor gene of
neoplasm [5,8-10].
It has been demonstrated that NDRG2 gene, in combi-
nation with TP53 gene, play a significant role in the
process of apoptosis in response to DNA lesion, and
NDRG2 is an inhibitor of cellular proliferation, regard-
less of the status of TP53 in cell [11]. The human
NDRG2 is inhibited by Myc oncogene. The to-date’s
research has indicated that an increased expression of
Myc oncogene is associated with decreased NDRG2
gene expression in many neoplasms [12]. Studies, per-
formed on neoplastic cell lines, have demonstrated that
methylation of NDRG2 gene promoter and point muta-
tions within the promoter in question cause a significant
reduction of NDRG2 gene activity [8].
Up to date, only one study concerning the NDRG2
gene expression in papillary thyroid carcinoma has been
published in the medical literature [13].
The goal of our study was an evaluation of mRNA
expression of NDRG2 gene in primary PTC and in its
metastases to regional lymph nodes.
Materials and methods
The procedures, as used in the study, had been
approved by the Ethical Committee of the Medical Uni-
versity of Lodz, Poland.
Postoperative tissue samples and macroscopically
changed lymph nodes of 16 patients with PTC consti-
tuted the study material. Out of them, neoplastic meta-
stases to regional lymph nodes were histopathologically
confirmed in 8 cases. The tumours were classified
according to the World Health Organisation’s Classifica-
tion (TNM) [14]. Tissue samples were collected after
total thyroidectomy, placed in storage buffer (RNA later
RNA Stabilisation Reagent of Qiagen) (Hilden, Ger-
many) and frozen in temperature of -70°C until isolation
of total RNA.
Selected clinical-pathological data of patients: age, sex,
histopathological diagnosis and TNM classification (acc.
to WHO) are presented in Table 1.
Isolation of total RNA and reverse transcription
Total RNA was extracted from tissues, using an RNeasy
Midi Kit (Qiagen, Hilden, Germany), according to the
manufacturer’s recommendations.
RNA concentration was spectrophotometrically
assessed by measuring absorbance at 260 and 280 nm.
Reverse transcription was performed in a personal
Mastercycler (Eppendorf, Hamburg, Germany), using 1
μg of total RNA in the presence of oligo d(T) (50 μM)
and MultiScribe™Reverse Transcriptase (50 U/μl) in a
total volume of 30 μl, including also: 10 × TaqMan
RT Buffer, MgCl2 solution (25 mM), dNTPs mixture
(10 nM), RNAse Inhibitor (20 U/μl) and nuclease-free
water (TaqMan Reverse) Transcriptase Reagents,
Applied Biosystems, Foster City, California, USA).
The reactions were incubated for 60 minutes at 27°C,
heated for 5 minutes to 95°C and then placed at 4°C.
Analysis of relative NDRG2 mRNA amount by real-time
PCR
An established Relative Qualification PCR assay for
NDRG2 mRNA expression was used (in ABI PRISM
7500 Sequence Detection System, Applied Biosystems),
according to the manufacturer’s protocol. PCR reactions
for NDRG2 were run with 50 ng of cDNA in a total
volume of μl, using a TaqMan™Universal PCR Master
Mix (Applied Biosystems, Foster City, California, USA)
and the predesigned and labelled primer/probe set
(Assay-on-Demand™Gene Expression assay mix
Hs01045114_g1). After an initial, 2-minute incubation at
50°C to allow uracil-N-glycosylase digestion and at 95°C
for 10 minutes to activate the Ampli Taq Gold™DNA
polymerase, both of which are provided by the Universal
PCR Master Mix, the samples were amplified through 50
bi-phasic cycles of 95°C for 15 s and of 60°C for 1 minute.
Macroscopically unchanged thyroid tissue served as a
calibrator. The amplification reactions were performed
in triplicate for each sample. Controls with no template
cDNA were used with each assay.
Table 1 Selected clinical and pathological data of
patients (age, gender), histopathological diagnosis, TNM
classification (acc. to WHO)
No: Age Gender Diagnosis Grade of progression in TNM scale
1. 80 F PTC pT1N0M0
2. 19 F PTC pT2N1bM0
3. 51 F PTC pT1N1M0
4. 60 M PTC pT1N1bM0
5. 72 F PTC pT4N1M0
6. 55 F PTC pT1N1M0
7. 42 F PTC pT1N0M0
8. 58 F PTC pT1N0M0
9. 33 F PTC pT1N0M0
10. 50 M PTC pT1N0M0
11. 56 M PTC pT4N0M0
12. 48 M PTC pT3N0M0
13. 43 F PTC pT1N1M0
14. 43 F PTC pT1N1M0
15. 57 F PTC pT1NxMx
16. 35 F PTC pT1N1M0
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dehydrogenase gene (GAPDH)w e r em e a s u r e da s
endogenous controls (reference gene), using the appro-
priate Assay-on-Demand™Gene Expression Mix
(Hs99999905_m1) (Foster City, California, USA).
Both gene expressions were measured for each tumour
sample in the same PCR reaction but in separate wells.
The Assay-on-Demand Gene Expression Mix consists
of 20 × mix of unlabelled PCR primers (18 μMf o r
each) and TaqMan™MGB probe (5 μM) with FAM™(6-
carboxy-fluorescein) at the 5’ end as a reporter dye and
a non-fluorescent quencher (TAMRA, 6-carboxy-tetra-
methylrhodamine) at the 3’ end. The two-minute, 50°C
step is required for optimal AmpErase™UNG activity,
when TaqMan™Universal Master Mix is used.
Fluorescence signal was measured in real-time in the
extension phase of the PCR reaction and the measure-
ment, proportional to the quantity of sample cDNA in
the reaction, was as an amplification curve against the
cycle number. A threshold value of fluorescence in the
exponential part of the amplification curve was selected
and, for each sample, the number of cycles was mea-
sured, which is needed by the signal to reach the thresh-
old (threshold cycle, CT) .T h el a r g e ra r et h eq u a n t i t i e s
of the starting material, the lower are CT values.
Data analysis
Data analysis was performed by means of the Taq-Man
SDS analysis software (Applied Biosystems).
Fluorescence emission data were determined as CT
values for each reaction and, for each sample, triplicate
CT values were averaged. The average CT value for
GAPDH was subtracted from the average NDRG2 CT
value to yield ΔCT value to yield ΔCT value. Normalisa-
tion to the reference gene (GAPDH) was necessary to
account for sample quantity and quality variations, as
well as for the variations of PCR efficiency among parti-
cular samples. The assay, described in this report,
involves ΔΔCT value determination. This is calculated
as: ΔΔCT = ΔCT test sample - ΔCT calibrator sample.
Statistical analysis
A non-parametric U-Mann-Whitney’s test was used to
compare the level of NDRG2 expression (RQ value)
between the cancer tissue and the unchanged tissue.
The Spearman’s rank correlation coefficient was applied
to determine the correlation between gene expression in
PTC and in the metastasis of the carcinoma to lymph
nodes. An assessment of relationships between the level
of NDRG2 expression and such parameters, as patient’s
age, sex, tumour stage (acc. to TNM) was performed
with the Spearmen’s rank correlation coefficient (age,
tumour stage) and U-Mann-Whitney test (sex). The
results are presented as basic statistics for RQ in
particular groups. The statistical significance was set at
p < 0.05.
Statistical analysis was performed by means of the
Statistica (StatSoft, Windows 7.1) software package.
Results
The clinical and pathological data regarding the cases of
PTC are shown in Table 1.
Differential expression of NDRG2 mRNA in primary
tumours and normal thyroid tissues
Figure 1 presents the observed mean values of NDRG2
mRNA expression level in PTC cells (n = 16) and in
normal thyroid tissue. The reference point for the stu-
died gene expression in PTC tissue was the value from
the averaging gene expression in macroscopically
unchanged thyroid tissues. The mean values of NDRG2
mRNA expression level in primary carcinoma (tumour)
cells were significantly lower vs. the of NDRG2 mRNA
expression level in normal thyroid tissue (p < 0.0001).
NDRG2 mRNA expression in primary tumours and
metastases
Figure 2 presents the recorded mean values of the
NDRG2 mRNA expression level in primary carcinoma
(tumour) cells (n = 8) and the mean values of the
NDRG2 mRNA expression level in metastases of the
carcinoma to regional lymph nodes (n = 8). A compari-
son of the mean values of those parameters between the
primary carcinoma (tumour) and metastases of that car-
cinoma to lymph nodes did not indicate any statistically
significant differences (p > 0.05). There was no statisti-
cally significant difference (p > 0.1) between the primary
tumours with metastases and without metastases in
regard to the NDRG2 mRNA expression.
A positive correlation was observed between the
NDRG2 mRNA expression level in primary carcinoma
(tumour) cells and the NDRG2 mRNA expression in the
same carcinoma metastases to lymph nodes (Rs =
0.7857; p < 0.05). It means that the decrease of the
NDRG2 mRNA expression level in primary carcinoma
(tumour) was accompanied by a fall in the NDRG2
mRNA expression level in metastases of the carcinoma
to lymph nodes.
NDRG2 mRNA expression depending on tumour stage
(TNM) and on patient’s age and sex
An evaluation of NDRG2 mRNA expression level,
depending on tumour stage in TNM classification was
performed for two groups: the first group included pT1
cases (Group pT1, n = 12) and the second one included
(because of the small number) combined cases of pT2,
pT3 and pT4 (Group pT2-pT4, n = 4) (Figure 3). A
comparison of the mean values of NDRG2 mRNA
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reveal any statistically significant differences (p > 0.05).
An evaluation of the NDRG2 mRNA expression level,
depending on patient age, was conducted in two groups:
in the group of PTC cases in both sexes (primary
tumour) at the age till 45 (n = 6) and in the group of
cases at the age above 45 (n = 10). The recorded mean
values of NDRG2 mRNA expression level did not differ
in any statistically significant way between those groups
(p > 0.05). The calculated correlation coefficient did not
show any significant relationship between the studied
parameters for the age (Rs = 0.0309; p > 0.1).
The mean values of NDRG2 mRNA expression level,
recorded in the group of women (n = 12) and in the
group of men (n = 4), did not show any statistically
significant differences between those groups, either
(p > 0.1).
Discussion
Papillary thyroid carcinoma, despite usually good prog-
nosis and low mortality rates, relatively frequently gives
metastases to regional lymph nodes, while, more rarely,
distant metastases (mainly to the lungs and bones). PTC
spreads mainly via lymphatic vessels. Metastases to
regional lymph nodes are observed in more than 50% of
operated patients [15]. The most important prognostic
factors in PTC include: age, sex, tumour size, encapsula-
tion, infiltration of perithyroid tissues, metastases and
postoperative thyroglobulin (Tg) levels [16,17].
In the reported study, the NDRG2 mRNA expression
levels were evaluated in PTC and in its metastases to
regional lymph nodes. In the study, we analysed post-
operative tissue material, from primary carcinoma
(tumour) and from macroscopically changed lymph
nodes, collected from 16 patients of both sexes.
Figure 1 Box and whisker chart.T h el e v e lo fNDRG2 mRNA expression in macroscopically unchanged thyroid tissue and in PTC. The boxes
represent means ± SEM. The results obtained with U-Mann-Whitney’s test point to a statistically significant difference of NDRG2 expression in
the investigated groups (p < 0.0001)
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tumour tissue and - in 8 cases - metastases of the carci-
noma to regional lymph nodes were identified.
Our present results have demonstrated a significantly
reduced NDRG2 mRNA expression levels in cells of
PTC (p < 0.0001). The recorded decrease of the NDRG2
mRNA expression level in primary carcinoma (tumour)
tissue vs. that in macroscopically unchanged thyroid tis-
sue, is in compliance with the results obtained by Zhao
et al. [13]. Those authors have been - till now - the first
who have published the results of studies on NDRG2
mRNA expression level in PTC. In the study by those
authors, decreased NDRG2 gene expression levels were
found in all the studied cases of PTC (n = 53) [13].
The results of our study confirm also the reports of
other authors, analysing the NDRG2 gene expression
level in various neoplasms [5,6,8-10]. Deng et al. [5]
analysed NDRG2 gene mRNA levels in cells of glioma
and in normal brain tissues. The results of these authors
revealed decreased NDRG2 expression in approximately
60% of gliomas vs. the expression levels in normal brain
tissue. Lusis et al. [8] noted that the expression of
NDRG2 in glioma was reduced at transcript and protein
level. In studies of Norwegian authors, it was demon-
strated that mRNA level of NDRG2 gene was signifi-
cantly lower in colon cancer tissue than in normal
tissues [10]. Also studies of NDRG2 gene expression in
gastric carcinoma revealed decreased expression levels
of the gene in some of the patients [18]. Moreover, the
authors suggested that studies of NDRG2 gene expres-
sion could be used as a prognostic factor for the survival
rate of patients with gastric carcinoma. In the group
with decreased expression of NDRG2 gene, the survival
rate of patients was significantly lower [18].
Other groups of researchers also described decreased
expression of NDRG2 gene in tissues from various
malignant neoplasms, e.g., in breast cancer [19], liver
carcinoma [20], clear cell renal carcinoma [21] and skin
carcinoma [22].
The process of neoplastic cell metastasis formation
includes an intricate complex of molecular and bio-
chemical events ("metastatic cascade”), including: the
Figure 2 Box and whisker chart.T h el e v e lo fNDRG2 mRNA expression in primary tumour and in metastases to regional lymph nodes. The
results obtained with Spearman’s rank correlation test did not demonstrate statistically significant differences between the level of expression in
the investigated groups (p > 0.05).
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angioinvasion, migration, reimplantation and prolifera-
tion of cells. One of the groups of the genes, which par-
ticipate in these processes, are suppressor genes in the
mechanism of metastasis formation, e.g., nm23, Kai1,
KISS1 [23]. During recent years, also NDRG2 gene has
been added to the group [7].
In our studies, we found no differences between
NDRG2 mRNA expression level in primary PTC and
mRNA expressions levels in metastases of the carcinoma
to regional lymph nodes. However, a positive correlation
was noted between NDRG2 mRNA expression levels in
primary PTC cells and the expression levels of NDRG2
mRNA in metastases of the carcinoma to lymph nodes,
what means that the decrease of the NDRG2 mRNA
expression level in the primary PTC was accompanied
by decreased mRNA expression levels of NDRG2 gene
in metastases of the carcinoma to lymph nodes. The
results of our study are similar to the results obtained
by Zhao et al. [13].
I nt h ep r e s e n ts t u d y ,w eh a v en o td e f i n e dt h er o l eo f
NDRG2 in PTC metastases to lymph nodes; that pro-
blem requires further analyses in subsequent studies
performed on higher numbers of cases.
In our studies, the prevailing number of cases with
PTC (n = 12) was qualified to pT1 group in TNM clas-
sification. The other, individual cases of PTC, qualified
to pT2, pT3 and pT4, were included into other separate
group (n = 4).
Ac o m p a r i s o no fNDRG2 gene expression in the two
studied groups of patients with various degree of
tumour progression, i.e., in Group pT1 and in Group
pT2-pT4, did no show any statistically significant differ-
ence. Interestingly, no correlation was documented in
the study of Zhao et al. between the expression of
NDRG2 gene and thyroid tumour size [13].
Figure 3 Box and whisker chart. The dependence of the level of NDRG2 mRNA expression on the tumour grade (pT, TNM scale) in two
investigated PTC groups: pT1 (n = 10) and pT2-pT4 (n = 4). The boxes represent means ± SEM. The results were obtained with Spearman’s rank
correlation test (p > 0.05).
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sion of NDRG2 gene and patient’s age. We have divided
the study group into two subgroups: the age till 45 (n =
6) and above 45 (n = 10). However, an analysis of the
correlation between the expression of NDRG2 mRNA
and the age of examined patients did not show any sta-
tistically significant differences. In other reports on dif-
ferent types of neoplasms, including PTC, no correlation
was shown between the expression of NDRG2 gene and
patients’ age [10,22]. Moreover, no correlation between
the expression of NDRG2 and patient’s sex, was demon-
strated in our study.
Conclusions
In conclusion, the results of our study demonstrated a
decreased level of NDRG2 gene expression in PTC vs.
macroscopically unchanged thyroid tissue, what may
indicate a potential role of NDRG2 gene in the develop-
ment and progression of this neoplasm. No correlations
were found between the expression of NDRG2 gene and
patient’s sex or age or the degree in tumour staging
(TNM) or its metastases. The evident lack of satisfactory
literature data, regarding the studies of NDRG2 gene
expression in PTC is an encouragement to undertake
f u r t h e rs t u d i e so nal a r g e rg r o u p so fp a t i e n t s ,w h i c h
m a ye n a b l et oe v a l u a t et h ep o t e n t i a lo fNDRG2 gene as
a biological marker in PTC.
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